OSR Health's Q2 Loss, Unremediated Material Weaknesses, and Shrinking Cash
OSRH sits 24% above its 52-week low of $0.251 on elevated volume (2.8× avg).
Summary
OSR Health's Q2 2026 filing shows unremediated material weaknesses, ineffective disclosure controls, a 72% revenue decline, and only $1.5 million in cash, with a dilutive convertible note contingent on Nasdaq compliance.
Key Events · Earnings and Guidance · OSRH
-
Material Weaknesses Unremediated
Management concluded that material weaknesses in internal control over financial reporting, first disclosed in the 2025 10-K, remain unremediated as of June 30, 2026. Disclosure controls and procedures were also ineffective.
-
Revenue Collapse
Net sales fell 72% year-over-year to $315,669 in Q2 2026, driven by a shift to a consignment model at subsidiary RMC. Gross margin improved to 27% from 3%, but operating loss was $3.03 million.
-
Cash Runway Tight
Cash and cash equivalents stood at $1.50 million as of June 30, 2026, down from $1.70 million at year-end 2025. Operating activities used $3.42 million in the first half of 2026.
-
Dilutive Financing Continues
The company issued 1,818,937 shares under its ELOC with White Lion in Q2 2026 for gross proceeds of $1.28 million. A $1.06 million convertible note carries a conversion price of $1.00 per share, or 90% of market price if Nasdaq deficiency is not cured by August 31, 2026.
Analysis · OSRH · Industrial Applications And Services
The Q2 2026 10-Q from OSR Health reveals that material weaknesses in internal controls remain unremediated, disclosure controls are ineffective, and cash has dwindled to $1.5 million. Revenue collapsed 72% year-over-year to $315,669, while the company continues to rely on a dilutive equity line of credit. Adding further dilution risk, the convertible note with White Lion Capital carries a contingent conversion price at a 10% discount to market if Nasdaq compliance isn't cured by August 31, 2026.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OSRH was trading at $0.31 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $10.9M. The 52-week trading range was $0.25 to $1.24. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.